SCHEMBL6926929

SCHEMBL6926929

O=S(=O)(Nc1ccccc1F)c1ccc2[nH]c(-c3cnccn3)nc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.51
MAPT P10636 6/20 0.48
TP53 P04637 3/20 0.48
TSHR P16473 1/20 0.48
GLO1 Q04760 2/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 2/20 0.43
HTR2C P28335 1/20 0.42
HTR2B P41595 1/20 0.42
CBFB Q13951 2/20 0.41
SLC40A1 Q9NP59 2/20 0.41
PKM P14618 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
GRM4 Q14833 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6924792 0.89 METAP2 (0.52) METAP2MAPTTP53TSHRGLO1
SCHEMBL6926724 0.89 CBFB (0.55) METAP2MAPTTP53TSHRGLO1
SCHEMBL6927054 0.86 TSHR (0.48) MAPTTP53TSHRGLO1MEN1
SCHEMBL6926782 0.84 MAPT (0.66) MAPTTP53TSHRMEN1KMT2A
SCHEMBL6927666 0.80 CBFB (0.54) METAP2MAPTTP53GLO1MEN1
SCHEMBL6926930 0.80 TSHR (0.51) MAPTTP53TSHRGLO1MEN1
SCHEMBL6925468 0.77 CBFB (0.53) METAP2MAPTTSHRGLO1MEN1
SCHEMBL10769891 0.77 METAP2 (0.57) METAP2MAPTKMT2ALMNACBFB
SCHEMBL6924722 0.77 TSHR (0.52) MAPTTP53TSHRMEN1KMT2A
SCHEMBL6925861 0.76 GLO1 (0.47) MAPTTP53TSHRGLO1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 US disclosed
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 US disclosed
WO-2011011722-A1 SUBSTITUTED BENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS VANDERBILT UNIVERSITY (US) 2011-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS GRM4, GRIK4, GRIA4 METAP2 1092/4885MAPT 3868/4885TP53 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.